Resmed (RSMDF) Payables (2010 - 2026)

Resmed (RSMDF) has reported Payables for 17 consecutive years, with $568.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 97.49% year-over-year to $568.9 million; the trailing twelve-month figure through Jun 2026 stood at $568.9 million (up 97.49% YoY), and the FY2026 full-year result was $568.9 million, up 97.49% from the prior year.
• Payables rose to $568.9 million in Q2 2026 per RSMDF's latest filing, from $533.2 million in the prior quarter.
• Across five years, Payables topped out at $568.9 million in Q2 2026 and bottomed at $160.7 million in Q2 2023.
• Historically, Payables has averaged $280.2 million across 5 years, with a median of $221.3 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Payables dropped 5.03% in 2023, then surged 129.38% in 2026.
• Over 5 years, Payables stood at $205.9 million in 2022, then rose by 3.1% to $212.3 million in 2023, then climbed by 8.44% to $230.2 million in 2024, then soared by 121.66% to $510.3 million in 2025, then gained by 11.48% to $568.9 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $568.9 million, $533.2 million, and $510.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.